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generate an effective immune response. In this study, total Leishmania antigen (TLA) formu-
lated with Montanide ISA 763 or R848 as adjuvants were evaluated as a first generation Leish-
mania vaccine in a murine model.
Methods: Immunization protocols were tested in BALB/c mice with a subcutaneous prime/
boost regimen with an interval of 3 weeks. Mice immunized with unadjuvanted TLA and
phosphate-buffered saline (PBS) served as control groups. On Day 21 and Day 36 of the proto-
col, we evaluated the humoral immune response induced by each formulation. Fifteen days
after the boost, the immunized mice were challenged with 1  105 promastigotes of Leish-
mania (Leishmania) amazonensis in the right footpad (RFP). The progress of the infection
was followed for 10 weeks; at the end of this period, histopathological studies were performed
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Montanide ISA 763 adjuvant in Leishmania vaccine 25Results: Vaccines formulated with Montanide ISA 763 generated an increase in the production
of immunoglobulin G (IgG; p < 0.05) compared with the control group. There were no statis-
tically significant differences in IgG1 production between the study groups. However, immuni-
zation with TLA-Montanide ISA 763 resulted in an increase in IgG2a compared to the
unadjuvanted control (p < 0.001). Also noteworthy was the fact that a significant reduction
in swelling and histopathological damage of the RFP was recorded with the Montanide ISA
763 formulation.
Conclusion: We conclude that the immunization of BALB/c mice with a vaccine formulated
with TLA and Montanide ISA 763 generated a protective immune response against L. (L.) ama-
zonensis, characterized by an intense production of IgG2a.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Leishmaniasis has a huge economic and public health
impact on endemic areas.1 Treatment of patients infected
with Leishmania is based solely on the use of chemo-
therapy, which is costly and has dangerous side effects.2
Currently, there are no preventive or therapeutic vac-
cines for any form of human leishmaniasis. Because of this
urgent need, much effort is being devoted to the devel-
opment of an effective vaccine.
The first vaccines tried against Leishmania used the
whole killed parasite as antigendthis strategy was imple-
mented from the 1940s to the present with variable re-
sults.3 Currently, new vaccines using recombinant DNA
technology are being developed, such as vaccines based on
recombinant viral vectors expressing parasite proteins4 or
recombinant proteins produced in bacteria.5 All of these
strategies involve sophisticated and expensive production
techniques that are difficult to implement in developing
countries.
Given the ease of production and some encouraging re-
sults, first generation vaccines should still be considered a
viable option.
In recent years, valuable basic information has been
collected in this field that could certainly help to improve
the design of such a strategy. A great deal of knowledge has
been already accumulated on the type of immunity that
should be induced in the vaccinated organism in order to
obtain a protective response. Protection studies in murine
models and analysis of the immune profile of self-healed
individuals clearly indicate the need to induce in the
vaccinated organism a T helper 1 (Th1) type response in
order to obtain protection.6 Also very important is the fact
that new adjuvants have been developed that offer multi-
ple ways to modulate the immune response according to
specific requirements.7,8
Many adjuvants have been tested in either first or sec-
ond generation experimental vaccines against leishmaniasis
and many of these have been shown to induce a Th1 im-
mune response.9e13
One adjuvant that has proven very effective is Mon-
tanide ISA 720, which is a mix of squalene and mannide
oleate emulsifier, to be used in combination with antigen in
a 70% V/V emulsion. Montanide ISA 720 has been used inexperimental vaccines alone or in combination with other
adjuvants with encouraging results.14e17
However, although much less toxic than mineral oil ad-
juvants, the reactogenicity of Montanide ISA 720 may be a
cause for concern and it is currently under investigation.
Undesirable reactogenicity in the form of sterile abscesses
associated with the use of Montanide ISA 720 as adjuvant
has been reported.18e21 Also of concern is the fact that
squalene induces chronic inflammatory arthritis in suscep-
tible animal models.22
In this study, we tested the efficiency of the adjuvant
Montanide ISA 763 in a first generation vaccine compared
with the Toll-like receptor (TLR) 7/8 ligand R848, which has
been shown to induce an enhanced Th1 response and pro-
tective immunity in mice following intradermal/subcu-
taneous vaccination.10 Montanide ISA 763 is a
biodegradable non-mineral oil adjuvant characterized by
its low reactogenicity; it is indicated for bird and fish vac-
cines (www.seppic.com), but it has never been tried in
Leishmania vaccines.
Methods
Animals
Inbred female BALB/c mice (8e9 weeks old) were used in
this study. Three independent experiments were carried
out with five mice per group. Mice were kept in standard
conditions with barriers, a controlled light cycle, and
controlled temperature. Food and water were provide ad
libitum. All animals were cared for in accordance with the
Guiding Principles in the Care and Use of Animals of the US
National Institutes of Health (NIH). All procedures were
approved by the Institutional Animal Care and
Use Committee of the School of Medical Science, Uni-
versidad Nacional de Cuyo (protocol approval no. 18/2013).
Parasites
The strain of L. (L.) amazonensis (MHOM/VE/84/MEL) used
in this study was kindly provided by Dr Miguel Angel
Basombrio, from the Experimental Pathology Institute,
National University of Salta, Argentina. Promastigotes of L.
26 D.E. Cargnelutti et al.(L.) amazonensis parasites were grown at 22C in Novy-
MacNeal-Nicolle medium (NNN) medium (Invitrogen) with
Roswell Park Memorial Institute (RMPI) 1640 (Life Technol-
ogies, San Diego, CA, USA) supplemented with 20% heat-
inactivated fetal bovine serum (FBS), 2 mM L-glutamine,
100 U/mL penicillin, and 100 mg/mL streptomycin (all from
Life Technologies, San Diego, CA, USA) and subcultured in
the same medium after 48e72 hours. Infectivity was
maintained by serial passage through mice.
Preparation of Leishmania antigens
Total Leishmania antigen (TLA) was prepared from late log-
phase promastigotes of L. (L.) amazonensis after a few
passages in liquid culture. Promastigotes were harvested by
centrifugation, washed three times with phosphate-
buffered saline (PBS) and disrupted by six to eight cycles of
freezing (80C) and thawing (56C). A similar procedure
was used to obtain soluble Leishmania antigen (SLA); after
six to eight cycles of freezing and thawing, the suspension
was centrifuged at 8000g for 20 minutes at 4C and super-
natant containing SLAwas collected. Protein contents of the
TLA and SLAwere estimated by the bicinchoninic acid assay.
The antigens were kept frozen at 70C until use.
Adjuvants
Montanide ISA 763 (Seppic, Puteaux, France) and R848
(InvivoGen, San Diego, CA, USA) were used as adjuvants in
this study.
Immunization
TLA (100 mg/mouse) was administered alone or formulated
with Montanide ISA 763 or R848. Montanide ISA 763 was
used as an oil-in-water emulsion (adjuvant/antigen ratio of
7:3) as per the manufacturer’s instructions and adminis-
trated subcutaneously in a volume of 200 mL in the inter-
scapular area of each mouse. R848 was prepared as a sterile
stock solution (20 mg/mL) in PBS, and the dose used was
20 mg/mouse; this vaccine was formulated in a volume of
50 mL of PBS and administered subcutaneously in the
interscapular area of each mouse. For booster vaccinations,
mice received the same vaccine formulation at the same
site 3 weeks after priming.
Infectious challenge
Mice were challenged with 1  105 stationary phase L. (L.)
amazonensis promastigotes 15 days after the boost. Para-
sites were injected into the right footpad (RFP) in a volume
of 50 mL. Lesion development was followed by weekly
measurement of footpad swelling using a digital caliper
(ED-10P; Schwyz).
Humoral response
The humoral immune responses induced by the experi-
mental vaccine formulations were evaluated by measuring
total specific IgG and IgG1 and IgG2a subtypes by enzyme-linked immunosorbent assay (ELISA) in serum samples
collected on Days 0, 21, and 36 of the immunization proto-
col. Briefly, 96-well microtitration plates (MaxiSorp; Nalge-
Nunc International, Pittsburgh, USA) were coated with
100 mL of SLA (3 mg/well) in PBS overnight at 4C. Nonspecific
binding sites were blocked with 1% bovine serum albumin
(BSA) in PBS at room temperature for 1 hour. After washing
with PBS containing 0.05% Tween-20 (Sigma Aldrich, St Louis,
USA), the plates were incubated at 37C for 1 hour with 1:100
dilutions of mice sera. The plates were then washed and
incubated with horseradish peroxidase-conjugated goat
antimouse IgG (Thermo Scientific, Pittsburgh, USA) diluted
1:10,000 for determination of total IgG, or with biotinylated
antimouse IgG1 or IgG2a (BD Pharmingen, New Jersey, USA)
diluted 1:1000 in blocking buffer. Finally, a color reaction
was developed by the addition of 100 mL/well of substrate
solution 3,30,5,50-tetramethylbenzidine supersensitive
(Sigma Aldrich, St Louis, USA) for 30 minutes. Absorbance
was determined at 450 nm using ELISA plate reader
(Multiskan EX; Thermo Scientific, Pittsburgh, USA).Histopathological analysis
Fragments of footpad lesion were fixed in Bouin’s 4% solu-
tion and embedded in paraffin. Sections of 5e6 mm were
stained with hematoxylin and eosin (H&E) for histopatho-
logical analysis. Images were taken with a Nikon Eclipse
E200 Microscope (Nikon Corporation, Japan) fitted with a
digital still camera Micrometric SE Premium (Nikon Corpo-
ration). Histological damage was calculated from observa-
tion of 10 different fields (40 magnification) of H&E-
stained sections from each animal. The histopathological
score grading system used to evaluate the degree of
inflammation was as follows: 0, none; 1, slight infiltration
of inflammatory cells; 2, moderate infiltration; 3, severe
infiltration.23 The total score was defined as the sum of all
the scores. Each slide was scored by two independent ob-
servers and the average score was used.Statistical analysis
Differences between groups were tested for significance by
one- and two-way analysis of variance (ANOVA) followed by
Tukey’s post-test using GraphPad Prism version 5.01 for
Windows (GraphPad Software, California, USA). A p value
<0.05 was considered statistically significant. Data shown
represent the mean values  standard error of the mean
(SEM) of three independent experiments.Results
Specific antibodies generated after immunization
BALB/c mice were injected twice by the subcutaneous
route at 3-week intervals as indicated above with 100 mg of
TLA formulated with Montanide ISA 763 or R848. The levels
of anti-Leishmania-specific total IgG as determined by
ELISA are shown as optical density (OD) values of a 1:100
serum dilution.
Montanide ISA 763 adjuvant in Leishmania vaccine 27At 21 days and 36 days after the prime immunization,
the three experimental vaccine formulations induced
seroconversion in all immunized mice. However, the OD
values of total IgG induced by TLA formulated with Mon-
tanide ISA 763 were greater than those obtained by im-
munization with TLA or TLA-R848, and showed a marked
booster effect on day 36 (Fig. 1).
Regarding the analysis of IgG subtypes induced by the
different formulations, there was no significant difference
in the production of the IgG1 subtype between all analyzed
groups (Fig. 2A).
However, as can be seen in Fig. 2B, the analysis of the
IgG2a subtype shows that the group of mice immunized
with TLA-Montanide reached values significantly higher
than those obtained in the groups of mice immunized with
TLA or TLA-R848 (p < 0.05).
In accordance with these data, the IgG2a/IgG1 ratio
(Fig. 2C) is higher in the TLA-Montanide group (1.14) than in
the TLA control (0.15) or TLA-R848 group (0.25).
The difference in magnitude of the total IgG OD values
compared with the anti-TLA values of the subtypes IgG1 and
IgG2a is likely due to use of different antimouse peroxidase
conjugated.
Protection assay of mice immunized with
TLA-Montanide or TLA-R848 against challenge
with L. (L.) amazonensis
The next step in this study was to evaluate if the immune
response induced in these groups of vaccinated mice was
able to protect themice against a challenge of live parasites.
Fifteen days after the booster, experimental groups were
challenged with 1  105 L. (L.) amazonensis promastigotes
and the level of infection was monitored for 10 weeks by
measuring footpad swelling. As shown in Fig. 3,Figure 1. Antileishmania IgG antibody responses to Leish-
mania (Leishmania) amazonensis antigen in vaccinated ani-
mals. Animals were vaccinated at two different time points
with PBS (control nonvaccinated), TLA alone, or TLA in
conjunction with Montanide ISA 763 (TLA-Montanide) or R848
(TLA-R848). Antibody levels were determined on Day 21 and
Day 36 postpriming. Data shown indicate mean IgG OD values
plus SEM in each vaccination group. * Significant differences in
comparison with control group, p < 0.05.
IgG Z immunoglobulin G; ns Z not significant; OD Z optical
density; PBS Z phosphate buffered saline; SEM Z standard
error of the mean; TLA Z total Leishmania antigen.immunization with TLA in the absence of an adjuvant pro-
vided no protection against infection, resulting in swelling
levels similar to those nonvaccinated mice injected with
PBS. Themice in the group vaccinatedwith TLA-R848 showed
no significantly greater protection than that obtained inmice
vaccinated with TLAwithout adjuvant. However, themice in
the group vaccinated with TLA-Montanide showed a signifi-
cant reduction in the size of the lesion in the footpad. The
differences in footpad thicknesses between the group
receiving TLA alone and the group receiving TLA plus Mon-
tanide ISA 763 became statistically significant (p < 0.05) by
week 8 after the challenge.
Thus we can conclude that TLA formulated with Mon-
tanide ISA 763 provided a partial but significant level of
protection.
Histopathology analysis of the tissue damage
induced after challenge of the vaccinated mice
with L. (L.) amazonensis
Ten weeks postchallenge a histopathological analysis of the
footpad lesions was performed in order to identify micro-
scopic features of the lesions in all groups. Microscopic
analysis of PBS, TLA, and TLA-R848 groups (Figs. 4AeC)
showed an intense inflammatory response characterized by
severe local inflammation with intense tissue destruction of
the dermis and epidermis. In these groups, extensive col-
lections of vacuolated and heavily parasitized macrophages
were observed. Amastigote forms were seen attached to
the wall of the parasitophorous vacuoles (Fig. 4F); the
number of parasitized macrophages was increased and
extensive areas of necrosis were observed. In these areas of
necrosis, free amastigote parasites were seen among in-
flammatory cells. Occasionally, areas of necrosis were
infiltrated by granulocytes, giving rise to micro-abscesses
(Fig. 4G).
In the TLA-Montanide-vaccinated mice, the presence of
a less infected and less vacuolated inflammatory cell pop-
ulation was observed (Fig. 4D). No epidermis destruction
was observed.
Histological changes in the lesions were semi-
quantitatively graded based on the criteria described by
Coˆrtes et al.23 A significant decrease in the histological
score index resulted from the analysis of the degree of
inflammation in the footpad lesion of the TLA-Montanide
group compared to the control (Fig. 5). These results
further confirm the significant level of protection offered
by the vaccination of mice with TLA-Montanide.
Discussion
For many years, many laboratories around the world have
worked on the development of an effective vaccine against
leishmaniasis. Early attempts (first generation vaccines)
used vaccines formulated with whole parasite antigens as a
source of antigen. Comprehensive analysis of the clinical
trials conducted in humans using this strategy showed that
encouraging as well as inconsistent results were obtained.24
Infecting patients with attenuated strains of Leishmania
was another strategy, and this gave positive results in some
cases.25
Figure 2. Antileishmania IgG subtype antibody responses to Leishmania (Leishmania) amazonensis antigen in vaccinated ani-
mals. Antibody levels were determined 36 days after the prime immunization. (A) IgG1 subtype; (B) IgG2a subtype; (C) IgG2a/IgG1
ratio. Data shown indicate mean IgG subtype OD values and ratio plus SEM in each vaccination group. *** Significant differences in
comparison with control group, p < 0.001. IgG Z immunoglobulin G; ns Z not significant; OD Z optical density; SEM Z standard
error of the mean.
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new strategies for the development of a vaccine are
available. Under this technology, vaccines based on purified
recombinant proteins of the parasite, recombinant viral
vectors, and genetic vaccines have been developed.4,5,26
However, these technologies involve production methods
that are highly sophisticated and are expensive to imple-
ment in many endemics areas, implying that the provisionFigure 3. Footpad swelling caused by challenge with infec-
tive promastigotes of Leishmania (Leishmania) amazonensis in
BALB/c mice vaccinated with PBS (control nonvaccinated), TLA
alone, or TLA in conjunction with Montanide ISA 763 (TLA-
Montanide) or R848 (TLA-R848). Fifteen days after the boost,
mice were challenged in the footpad with 1  105 promasti-
gotes of L. (L.) amazonensis (MHOM/VE/84/MEL). Following
challenge, the mice were monitored every week for 10 weeks
by measurement of lesion swelling using a digital caliper.
Footpad swelling is given as means plus SEM. PBSZ phosphate
buffered saline; SEM Z standard error of the mean;
TLA Z total Leishmania antigen.of vaccines for these areas would rely on an external
source.
In an early development, the group of Mayrink prepared
a vaccine against cutaneous leishmaniasis utilizing whole
parasite antigens obtained from stocks derived from pa-
tients.27 Later, the same group developed a vaccine based
on L. (L.) amazonensis that was effective in preventing the
disease, and when administered in combination with anti-
monium salts, demonstrated immunotherapeutic activity.28
In a recent contribution, the same group29 showed in a
clustered, randomized clinical trial a significant reduction
in the number of cases of American cutaneous leishmaniasis
in a group vaccinated with a nonadjuvanted first generation
vaccine obtained from L. (L.) amazonensis compared with
the placebo group.
A vaccine developed by Convit’s group30 in Venezuela
using whole antigenic extracts combined with Bacillus
CalmetteeGue´rin (BCG) as adjuvant administered to pa-
tients with American cutaneous leishmaniasis had an effi-
cacy of 91.2e98.7% clinical remission. The use of BCG as
adjuvant is based on the known fact that when it is co-
administered with antigen, it induces a strong immune
response with a Th1 profile.
Analysis of those human trials that have yielded positive
results indicates that there is still the possibility of devel-
oping a vaccine formulated with parasite extracts. For this
goal to be successful it will be essential to formulate the
vaccine with the appropriate adjuvant. Analysis of the data
obtained in the murine model as well as analysis of the
clinical course of infected patients clearly indicates the
importance of the development of Th1 immunity to protect
organisms from infection.6
In the present study, we have investigated two first
generation vaccine formulations containing whole L. (L.)
Figure 4. Histological outcome in the footpad infection site of the different vaccinated groups after 10 weeks of the challenge.
(A) Mice vaccinated with PBS (control nonvaccinated). (B) Mice vaccinated with TLA. (C) Mice vaccinated with TLA formulated with
R848 (TLA-R848). (D) Mice vaccinated with TLA formulated with Montanide ISA 763 (TLA-Montanide). (E) The histological outcome
of noninfected mice was used as an indicator of the normal histoarchitecture of the footpad. (F) Amastigote forms attached to the
wall of the parasitophorous vacuoles and (G) necrosis areas infiltrated by granulocytes were seen in groups PBS, TLA, and TLA-R848.
Figures are representative of three animals analyzed in each vaccinated group. PBS Z phosphate buffered saline; TLA Z total
Leishmania antigen.
Montanide ISA 763 adjuvant in Leishmania vaccine 29amazonensis antigenic extract formulated with a TLR7/8
agonist or with Montanide ISA 763 as adjuvants. The effi-
cacy of these vaccines was evaluated by the level of pro-
tection generated in susceptible BALB/c mice after
challenge with live parasites.The results of this work demonstrate that the subcu-
taneous administration of TLA formulated with Montanide
ISA 763 generates a protective immune response against
infection by L. (L.) amazonensis in BALB/c, characterized
by a high production of the IgG2a subtype with a low
Figure 5. Histopathological indexes of the footpad infection site of the different vaccinated groups after 10 weeks of the
challenge. Histopathological damage scores used to evaluate the degree of inflammation were: (A) none; (B) slight infiltration of
inflammatory cells; (C) moderate infiltration; (D) severe infiltration. Panel (E) shows the score indexes of the different groups
calculated after 10 weeks of the challenge. Data shown indicate mean values plus SEM in each vaccination group. *** Significant
differences in comparison with control group, p < 0.001. ns Z not significant; PBS Z phosphate buffered saline; TLA Z total
Leishmania antigen.
30 D.E. Cargnelutti et al.production of IgG1 (Figs. 2A and B) and a IgG2a/IgG1 ratio
greater than 1.
Because IgG2a and IgG1 have been used as indicators of
the induction of Th1 and Th2 responses, respectively, the
IgG2a/IgG1 ratio can help to define the T cell phenotype
induced by vaccination.31e33 Thus, IgG2a/IgG1 ratios were
used as indicators of Th1- or Th2-based responses induced
by immunization.
It is interesting to note that the TLA-Montanide formu-
lation was able to induce a high IgG2a/IgG1 ratio (Fig. 2C)
and protection of mice against experimental challenge with
L. (L.) amazonensis, while the vaccine formulated withR848 induced much higher IgG1 than IgG2a subtype and
failed to generate protection in infected mice (Fig. 3).
The vaccine formulated with R848 did not generate
protective immunity against the challenge with L. (L.)
amazonensis and produced low levels of IgG2a (Fig. 2B) and
an IgG2a/IgG1 ratio lower than one (Fig. 2C). This result
might disagree with the work of Zhang and Matlashewski10,
which demonstrated in a murine model of infection with L.
major that immunization in the footpad with TLA-R848
protects mice from infectious challenge, while the same
formulation administered intramuscularly did not protect
against infection.
Montanide ISA 763 adjuvant in Leishmania vaccine 31However, it should be taken into account that it is well
known that the route of immunization has a significant in-
fluence on the effectiveness of a vaccine. In the case of the
work of Zhang and Matlashewski10, the delivery of the vac-
cine was by injection in the footpad, which is one of themost
frequently used methods in murine models for evaluation of
experimental vaccine formulations against Leishmania. This
route of vaccine delivery is assumed to be a mixed subcu-
taneous and intradermal route.34 However, in our case the
vaccineswere administered in themouse interscapular area,
which is considered a purely subcutaneous route,35 while in
the work of Zhang and Matlashewski,10 the TLA-R848 was
effective when it was injected in the footpad, which, as
mentioned above, is considered a combination of the sub-
cutaneous and intradermal route. We believe that the
different routes used for the administration of vaccines
could explain the different results obtained in our work
compared to those of Zhang and Matlashewsky.10
In conclusion, Montanide ISA 763 adjuvant appears to be
a promising candidate for the development of a new
Leishmania vaccine due to its safety and ability to induce a
protective immune response, characterized by a high pro-
duction of the IgG2a subtype with a low production of IgG1,
and skewing the immune response toward a Th1 profile
when it is given by the subcutaneous route. It would be
important to carry out further investigations on the po-
tential use of Montanide ISA 763 as an adjuvant for Leish-
mania vaccines in nonhuman primate models. Such studies
would provide a guide for the design of vaccine formula-
tions for clinical trials.
Based on the results shown in this study in terms of the
quality of the immune response obtained with a vaccine
formulated with Montanide ISA 763 and the fact that the
vaccine confers partial protection against a challenge of
living parasites, we suggest that Montanide ISA 763 should
be considered as a candidate adjuvant for the development
of a new vaccine against Leishmania.
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